Adalimumab is effective uveitis treatment

Article

Adalimumab is an effective treatment for patients with active non-infectious uveitis, according to a recent investigation.

Adalimumab is an effective treatment for patients with active non-infectious uveitis, according to a recent investigation.

Dr Bianca Carola Dobner et al., Department of Ophthalmology, Interdisciplinary Uveitis Centre, University of Heidelberg, Heidelberg, Germany, conducted a retrospective study on 60 patients who were treated with adalimumab.

Outcome measures for efficacy were reduction of macular oedema by optic coherence tomography, visual acuity, anterior chamber cells, reduction of frequency of flares and reduction of prednisone dose during the treatment.

Of the patients assessed, 49 improved while the remaining 11 were administered additional or alternative immunosuppressive treatment. At the last follow-up 47 patients still received adalimumab treatment.

Side effects, including liver enzyme elevation and furunculosis, occurred in three patients. Treatment was stopped in 13 patients due to inefficacy, in three patients due to side effects, one pregnant patient and one patient who died.

Overall, the results of this study demonstrated that adalimumab is effective for the treatment of uveitis in up to 80% of patients. To read the abstract please visit the British Journal of Ophthalmology.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.